Leerink launched coverage of Mersana Therapeutics (NASDAQ:MRSN) with an “outperform” rating and $23 one-year price target, representing an approximate $500-million valuation. The stock closed at $14.05 on July 21.Read More
The FDA has granted orphan drug designation to closely-held Soricimed Biopharma’s peptide, SOR-C13, for the treatment of pancreatic cancer, following a similar designation for ovarian cancer
In a statement, Paul Gunn, president and CEO of Soricimed, said receiving orphan drug status in both ovarian and pancreatic cancer highlights the unmet medical need and the potential of SOR-C13 to address these devastating cancers.Read More
Closely-held Soricimed Biopharma has announced the members of its newly formed Clinical Advisory Board (CAB).
The CAB, comprising key thought leaders in the treatment of cancer and novel anti-cancer targets, will provide Soricimed with ongoing expert strategic guidance on the continued clinical development of its lead anti-cancer drug candidate, SOR-C13, and its preclinical oncology pipeline.Read More